PHR logo

PHREESIA INC

PHRNYSE
πŸ† #2827 by market capEarnings Dec 7US Equity
$364.28β–Ό $21.86 (βˆ’6.00%)
Simulated price
πŸ””
Track PHR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 6.0%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$624M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+14.5%
Healthy
πŸ“ŠGross Margin
63.5%
High
πŸ’΅FCF Margin
15.3%
Healthy
βš–οΈP/S Ratio
1.2x
Cheap
Otter Score
92
Very Good
No chart data available for PHR.

Trading Snapshot

Day Range
$361.94 – $371.06
52-Week Range
$7.77 – $24.25
Volume
$1.64B
Avg Volume
$1.88B
Shares Outstanding
61.8M
Next Earnings
Dec 1, 2026

Fundamentals Snapshot

Annual Revenue
$481M
Last Q Revenue
$129M
P/E Ratio
58.7
P/S Ratio
1.2x
EPS (TTM)
$0.17
Dividend Yield
0.00%
Dilution (1yr)
+1.6%

Why Investors Own PHR

  • βœ“High-growth profile β€” revenue up +36.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 63% gross margin and 7% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PHR logo

PHREESIA INC

PHR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$481Mβ–² +14.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.9%β–² +0.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$7Mβ–Ό βˆ’88.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$68Mβ–² +716.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
62.5Mβ–² +1.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5Mβ–Ό βˆ’$91M YoY
StockOtter Β· stockotter.space

About PHREESIA INC

Phreesia, Inc. offers a comprehensive, cloud-based software-as-a-service (SaaS) and payment platform specifically designed for the healthcare industry in the United States and Canada. Its flagship Phreesia Platform streamlines the patient intake process and facilitates integrated patient payment processing. The platform is accessible via multiple modalities, including Phreesia Mobile (a patient-facing mobile application), Phreesia Dashboard (a web-based portal for healthcare clients), self-service tablets known as PhreesiaPads, and on-site Arrivals Kiosks. The Phreesia Platform integrates a suite of specialized modules: An automated patient self-registration system. A revenue cycle management solution providing insurance verification, point-of-sale payment applications, and cost estimation tools. Access solutions for online appointment scheduling, reminders, and referral tracking. A life sciences solution delivering targeted, clinically relevant marketing content to patients. Additionally, a clinical support solution gathers clinical intake and patient-reported outcome (PRO) data across approximately 25 specialties, and enables healthcare clients to communicate with patients via surveys, announcements, text and email messaging, and health campaigns. Dedicated COVID-19 support modules assist with vaccine delivery management, identifying vaccine-hesitant individuals, screening for risk factors, facilitating contactless check-in, and managing telehealth visit intake. Phreesia serves a diverse clientele, including individual patients; single and multi-specialty practices, along with health systems; and pharmaceutical, medical device, and biotechnology firms. Established in 2005, the company maintains its headquarters in Raleigh, North Carolina.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Very Good
92/100

Analyst Price Target

β“˜
Average Target
$472.24
β–² +29.6% Upside
High Target$563.22
Low Target$412.70
Based on 34 analysts

Latest News & Updates